ID   PH101
AC   CVCL_RT30
DR   Wikidata; Q54947350
RX   DOI=10.5833/jjgs.28.12;
RX   PubMed=8473041;
RX   PubMed=8507543;
CC   Population: Japanese.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 5
//
RX   DOI=10.5833/jjgs.28.12;
RA   Yamaguchi Y., Noma K., Miyahara E., Funakoshi M., Takashima I.,
RA   Toge T.;
RT   "Augmented susceptibility of CDDP-treated human pancreatic cancer cell
RT   line, PH101, to lysis by effector lymphocytes.";
RL   Nihon Shokaki Geka Gakkai Zasshi 28:12-16(1995).
//
RX   PubMed=8473041; DOI=10.1002/ijc.2910530626;
RA   Nishiyama M., Saeki S., Aogi K., Hirabayashi N., Toge T.;
RT   "Relevance of DT-diaphorase activity to mitomycin C (MMC) efficacy on
RT   human cancer cells: differences in in vitro and in vivo systems.";
RL   Int. J. Cancer 53:1013-1016(1993).
//
RX   PubMed=8507543; DOI=10.1007/BF01877384;
RA   Kawami H., Yoshida K., Yamaguchi Y., Saeki T., Toge T.;
RT   "The expression and biological activity of IL-2 receptor on a human
RT   pancreas cancer cell line.";
RL   Biotherapy 6:33-39(1993).
//